Skip to main content
. 2012 Dec 7;7(12):e50325. doi: 10.1371/journal.pone.0050325

Table 1. Baseline characteristics of mothers whose children were children enrolled in the trial of quarterly albendazole versus placebo from age 15 months to five years.

Albendazole Placebo Albendazole
Number of mothers with children randomiseda 994 1002
Age in years, mean ± SD 23.95±5.38 23.76±5.43
Education (4 mv)b
None 36 (4%) 33 (3%)
Primary 498 (50%) 509 (51%)
Secondary 381 (38%) 362 (36%)
Tertiary 79 (8%) 94 (9%)
Household socioeconomic status (41 mv)c
(low) 1 48 (5%) 67 (7%)
2 77 (8%) 88 (9%)
3 320 (33%) 289 (30%)
4 280 (29%) 281 (29%)
5 190 (19%) 203 (21%)
(high) 6 62 (6%) 50 (5%)
Gravidity
1 247 (25%) 265 (26%)
2–4 582 (59%) 571 (57%)
≥5 165 (17%) 166 (17%)
Trimester at treatment (3 mv)
2 512 (52%) 506 (51%)
3 482 (48%) 493 (49%)
Maternal history of asthma (1 mv) 19 (2%) 22 (2%)
Helminth infections
Hookworm (7 mv) 459 (46%) 409 (41%)
S. mansoni (7 mv) 189 (19%) 177 (18%)
M. perstans (8 mv) 222 (22%) 201 (20%)
HIV positive 109 (11%) 94 (9%)
Malaria parasitaemia (36 mv) 104 (11%) 93 (9%)
Owns mosquito net (3 mv) 494 (50%) 519 (52%)
Intermittent preventive treatment for malaria during pregnancy (91 mv)
1 dose 230 (24%) 209 (22%)
2 doses 626 (66%) 654 (68%)
≥3 doses 87(10%) 99 (10%)
Maternal tetanus immunisation during pregnancy
0 doses 220 (22%) 231 (23%)
1 dose 600 (60%) 592 (59%)
≥2 doses 174 (18%) 179 (18%)
Maternal treatment
Albendazole+praziquantel 244 (24%) 256 (26%)
Albendazole placebo+praziquantel 247 (25%) 249 (25%)
Albendazole+praziquantel placebo 247 (25%) 257 (26%)
Double placebo 256 (26%) 240 (24%)
a

The number of mothers with children randomised is lower than the number of children randomised due to 20 sets of twins.

b

mv: missing values.

c

Household socioeconomic status was scored based on building materials of the home, number of rooms and items owned, “1” representing lowest and “6” representing highest status.